Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory,Open-label,and Single Center Study to Evaluate the Safety and Efficacy of ET-02 in Patients With Relapsed or Refractory B-cell Malignancies(NHL/ALL).

NCT04933825 is registered in ClinicalTrials.gov with EdiGene (GuangZhou) Inc. as lead sponsor.

NCT NCT04933825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04933825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory,Open-label,and Single Center Study to Evaluate the Safety and Efficacy of ET-02 in Patients With Relapsed or Refractory B-cell Malignancies(NHL/ALL).
Lead sponsor
EdiGene (GuangZhou) Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
July 20, 2021
Completion date
September 30, 2024
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b-cell malignancy(nhl/all)